

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/662,654
Applicant: R.L Jenkins *et al.*
Filed: September 15, 2003
TC/A.AU.: Unassigned
Examiner: Unassigned

Confirmation No.: 1181

Docket No.: 09770.105001 SMF
Customer No.: 20786
Title: Methods and Compositions for the Use of D-Malic Acid to Decrease
Serum Triglyceride, Cholesterol and Lipoprotein Levels

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

February 11, 2004


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the attached Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of all listed documents are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the Applicants may have under applicable statutes, rules of practice in patent cases, or otherwise.

Applicant does not believe any fees are due because this paper is being submitted before the mailing of a first Office Action on the merits of the application, as under 37 C.F.R. § 1.97(b)(3). However, if required, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.

Respectfully submitted,


Stephanie D. Adams
Reg. No. 47,378

King & Spalding LLP
191 Peachtree Street N.E.
45th Floor
Atlanta, Georgia 30303
Office: 404/572-4600
Fax: 404/572-5145



INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing Under 37 CFR 1.10


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below-identified date.

Deposit Date: February 11, 2004

A handwritten signature in cursive script that reads "Minikia Blair".

Minikia D. Blair
Legal Assistant

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **3**

Complete if Known

Application Number	10/662,654
Filing Date	September 15, 2003
First Named Inventor	R.L. Jenkins
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	09770.105001 SMF

3389391 2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages / Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	2,972,566		Kitahara <i>et al.</i>	02-21-1961	
	AB	3,063,910		Abe <i>et al.</i>	11-13-1962	
	AC	4,029,812		Wagner <i>et al.</i>	06-14-1977	
	AD	4,076,841		Wagner <i>et al.</i>	02-28-1978	
	AE	4,078,084		Wagner <i>et al.</i>	03-01-1978	
	AF	4,522,811		Eppstein <i>et al.</i>	06-11-1995	
	AG	4,752,616		Hall <i>et al.</i>	06-21-1988	
	AH	4,912,042		Laumen	03-27-1990	
	AI	4,954,514		Kita <i>et al.</i>	09-04-1990	
	AJ	4,965,252		Kuhrts	10-23-1990	
	AK	5,120,766		Holloway <i>et al.</i>	06-09-1992	
	AL	5,155,250		Parker <i>et al.</i>	10-13-1992	
	AM	5,206,247		Regnier <i>et al.</i>	04-27-1993	
	AN	5,262,439		Parthasarathy	11-16-1993	
	AO	5,608,095		Parker <i>et al.</i>	03-04-1997	
	AP	5,627,205		Regnier <i>et al.</i>	05-06-1997	
	AQ	5,705,515		Fisher <i>et al.</i>	01-06-1998	
	AR	5,746,223		Williams	05-05-1998	
	AS	5,783,600		Bisgaier <i>et al.</i>	07-21-1998	
	AT	5,824,449		Ohnishi <i>et al.</i>	10-20-1998	
	AU	5,948,435		Williams	09-07-1999	
	AV	6,004,936		Kisilevsky	12-21-1999	
	AW	6,011,048		Mathvink <i>et al.</i>	01-04-2000	
	AX	6,034,106		Biftu <i>et al.</i>	03-07-2000	
	AY	6,043,253		Brockunier <i>et al.</i>	03-28-2000	
	AZ	6,090,836		Mams <i>et al.</i>	07-18-2000	
	AAA	6,147,250		Somers	11-14-2000	
	AAB	6,193,967	B1	Morganelli	02-27-2001	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		
				Filing Date	September 15, 2003	
				First Named Inventor	Unassigned	
				Group Art Unit	Unassigned	
Attorney Docket Number	09770.105001 SMF					
Sheet	2	of	3			

3389391 2

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	BA	EP	0,348,203	A1	Shionogi & Co.	12-27-1989		
	BB	EP	0,405,788	A2	Shionogi & Co.	01-02-1991		
	BC	EP	0,621,255	A1	Adir et Compagnie	10-26-1994		
	BD	EP	0,763,527	B1	Adir et Compagnie	03-19-1997		
	BE	FR	2130975		Aries	11-10-1972		
	BF	FR	2133024		Aries	11-24-1972		
	BG	FR	2134810		Aries	12-08-1972		
	BH	FR	2140769		Aries	01-19-1973		
	BI	FR	2140771		Aries	01-19-1973		
	BJ	FR	2168137		Dynachim	08-31-1973		Y
	BK	JP	2001/197897		Mitsubishi Chemicals	07-24-2001		Y
	BL	JP	JP 5271147		Mitsubishi Petrochem	10-19-1993		Y
	BM	WO	95/15760		Merrel Dow Pharmaceuticals	06-15-1995		
	BN	WO	97/15546		Nippon Shinyaku	05-01-1997		
	BO	WO	98/40375		G.D. Searle	09-17-1998		
	BP	WO	98/51289		Atherogenics	11-19-1998		
	BQ	WO	98/51662		Atherogenics	11-19-1998		
	BR	WO	00/26184		Nematel Dr. Rudolf Eidenschink	05-11-2000		
	BS	WO	00/38725		G.D. Searle	07-06-2000		
	BT	WO	01/70757	A2	Atherogenics	09-27-2001		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
.	BU	ALAUPOVIC, P., In <u>Handbook of Electrophoresis</u> . Vol. 1, pp. 27-46 (1980).		
	BV	BRADLY, W.A. and Gotto, A.M., American Physiological Society, Bethesda, MD, pp 117-137 (1978)		
	BW	BROWN, L., <i>et al.</i> , "Transdermal Delivery of Drugs," <i>Annual Review of Medicine</i> , 39:221-229 (1988).		
3	BX	CAREW, T.E., <i>et al.</i> , "Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants <i>in vivo</i> can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84:7725-7729 (1987).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				Filing Date	September 15, 2003
				First Named Inventor	Unassigned
				Group Art Unit	Unassigned
Sheet	3	of	3	Attorney Docket Number	09770.105001 SMF

3389391_2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	CA	DE MEGLIO, P., <i>et al.</i> , "New Derivatives of Clofibrate and Probucol: Preliminary Studies of Hypolipemic Activity," <i>Farmaco, Ed. Sci.</i> , 40 (11), 833-44 (1985).	
	CB	DOLPHIN, P. J., "Lipoprotein metabolism and the role of apolipoproteins as metabolic programmers," <i>Can. J. Biochem. Cell. Biol.</i> 63, 850-869 (1985).	
	CC	ENDO, A., "The discovery and development of HMG-CoA reductase inhibitors," <i>J. Lipid Res.</i> 33, 1569-1582 (1992).	
	CD	FOODY, J.M., <i>et al.</i> , "HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-Year experience from the Cleveland Clinic Foundation," <i>Circulation</i> , 102 (19 suppl 3), III-90 to III-94 (2000).	
	CE	GLOMSET J. A., <i>et al.</i> , "The metabolic role of lecithin: Cholesterol acyltransferase: Perspectives from Pathology," <i>Advan. Lipid Res.</i> , 11, 1-65, (1973).	
	CF	GRUNDY, S. M., "HMG-CoA reductase inhibitors for treatment of hypercholesterolemia," <i>New Engl. J. Med.</i> 319, 24-33 (1988).	
	CG	JIN, F.-Y., <i>et al.</i> , "Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells," <i>Arterioscler. Thromb. Vasc. Biol.</i> 17, 2020-2028 (1997).	
	CH	JIN, F.-Y., <i>et al.</i> , "Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2), <i>Arterioscler. Thromb. Vasc. Biol.</i> , 16, 1052-1062 (1996).	
	CI	MACIEJKO J. J. <i>et al.</i> , "Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease," <i>New England J. Med.</i> 309(7), 385-389 (August 18, 1983).	
	CJ	McCALL, M. R., <i>et al.</i> , "Transformation of HepG2 nascent lipoproteins by LCAT: modulation by HepG2 d > 1.235 g/ml fraction," <i>J. Lipid Res.</i> , 34, 37-48 (1993).	
	CK	McKENZIE, A., <i>et al.</i> , "Optical activation of racemic acid by d-malic acid," <i>J. Chem. Soc.</i> , 123, 2875-2880 (1923).	
	CL	MINGPENG, S., <i>et al.</i> , "The protective role of high-density lipoproteins in atherosclerosis," <i>Experimental Gerontology</i> , 34 (4) 539-48 (1999).	
	CM	PATSCH, J. R., <i>et al.</i> , "Formation of high density lipoprotein ₂ -like particles during lipolysis of very low density lipoproteins <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci.</i> , 75, 4519-4523 (1978).	
	CN	SICART, R., <i>et al.</i> , "Reduction of cholesterol transported in Apo B-rich lipoproteins in spontaneously hypercholesterolemic hamsters fed an apple-supplemented diet," <i>Ann. Nutr. Metab.</i> 31, 1-8 (1987).	
	CO	STEDRONSKY, E. R., "Interaction of bile acids and cholesterol with non-systemic agents having hypocholesterolemic properties," <i>Biochim. Biophys. Acta</i> 1210, 255-287 (1994).	
	CP	WILSON M. D., <i>et al.</i> , "Review of cholesterol absorption with emphasis on dietary and biliary cholesterol," <i>J. Lipid Res.</i> 35, 943-955 (1994).	

3389391_2

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.